The appliance from Lykos — a drug organization incubated by the Multidisciplinary Association for Psychedelic Reports, or MAPS — arrived for the FDA under a cloud of controversy. Former demo participants experienced alleged adverse events were not noted — which includes inner thoughts of suicidality once the remedy — and that bias between I